Navigation Links
ImaginAb, Inc. and Eurogentec S.A. Collaborate to Produce Antibody Fragments in Pichia
Date:1/31/2011

LOS ANGELES, Jan. 31, 2011 /PRNewswire/ -- ImaginAb, Inc. and Eurogentec S.A. announce a development collaboration to establish a novel system for producing engineered antibody fragments. The two companies will produce ImaginAb's optimized antibody fragments with Eurogentec's high-performance Pichia pastoris expression system. Leveraging Eurogentec's expertise in cGMP manufacturing of recombinant proteins, the collaboration will accelerate the development of ImaginAb's rich pipeline of targeted molecular imaging agents for the diagnosis and treatment management of cancer and autoimmune diseases.

"With our rapidly expanding pharma client base worldwide, ImaginAb is leveraging multiple manufacturing technologies to increase our capacity for fast, reliable protein production," said Dr. Christian Behrenbruch, CEO of ImaginAb. "Eurogentec's Pichia technology has the potential to enable us to take a fresh look at how we do extremely rapid and cost-effective translation into humans with our antibody fragment technology."

Dr. Philippe Cronet, CSO of Eurogentec commented, "We are very committed to exploring new manufacturing strategies for ImaginAb's unique products. Our technology platform is well suited to a variety of recombinant proteins including the important class of antibody fragment proteins such as those under development by ImaginAb".

About ImaginAb

Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.

About Eurogentec

Eurogentec is a cGMP accredited Contract Manufacturing Organization (CMO) offering process development and cGMP manufacturing services since 1994. Eurogentec manufactures recombinant proteins, plasmids, vaccines and conjugates in compliance with EU 2003/94/EC and US FDA 21CFR 210 and operates a full-service, state-of-the-art cGMP facility located in Belgium. In 2010, Eurogentec became part of Kaneka Corporation, Osaka, Japan. For more information about Eurogentec, visit www.eurogentec.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Anna Wu

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=91513


'/>"/>
SOURCE ImaginAb, Inc.; Eurogentec S.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration
2. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
3. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
4. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
5. DuPont and USDA ARS to Collaborate on New E. coli Test in Beef
6. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
7. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
8. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
9. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
10. Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
11. febit and TGen Collaborate to Study New DNA Capture Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 Avillion LLP, ... appointment of Mark Weinberg , MD MBA as Chief Medical ... , USA . ... Dr Weinberg has spent more than 17 years ... 20" pharma companies to micro-cap biotech. Over the course of his ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 Report ... Ophthalmic Devices Market? Which areas are going to grow ... potential revenues to 2026, assessing data, trends, opportunities and ... and graphs. Discover the most lucrative areas in the ... lets you assess forecasted sales across the all the ...
(Date:1/19/2017)... 2017 Conference Call and Webcast to Follow ... it will release results for the fourth quarter of 2016 on ... ... call at 4:30 PM ET on Wednesday, February 15, 2017, during ... financial results and other corporate activities. To participate in the conference ...
Breaking Medicine Technology:
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of its new medical office in Petaluma, located at 167 Lynch Creek Way. ... access to SRO sports medicine and rehabilitation services and on-site x-ray ...
(Date:1/20/2017)... ... 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built ... is mounted on wheels, it can be wheeled out of the way and stored when ... the deck. "We have transformed the feedback from customers into specific enhancements and created a ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body ... oils, announced the company had a successful visit to the 2017 ECRM Diet, Vitamin ... companies that work in the nutritional, sports and health industries a chance to meet ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company ... with school-aged children since the holiday season. , “It happens every year around ... sharing hugs and taking photos, which is the head-to-head gateway that lice need to ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years ... Betsy, the clinical trial has been life-saving as she has been on the ... Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but ...
Breaking Medicine News(10 mins):